Avrobio is set to incorporate its plato platform into its FAB-201 Phase II trial and dose patients at clinical sites in the US.

The move comes after the US Food and Drug Administration (FDA) cleared the company’s investigational new drug application for its gene therapy candidate AVR-RD-01 to treat Fabry disease.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The plato platform comprises a four-plasmid vector system, automation of a closed cell manufacturing process and a conditioning regimen that uses therapeutic drug monitoring.

Avrobio president and CEO Geoff MacKay said: “We are very pleased that FAB-201 remains on track to expand into sites in the US in the second half of 2019.

“We are very pleased that FAB-201 remains on track to expand into sites in the US in the second half of 2019.”

“Importantly, we believe this US FDA clearance represents a major milestone as we transition to plato, our optimised commercial-scale platform for our anticipated future worldwide commercialisation activities.

“We have now achieved initial regulatory clearances for clinical trials in Australia, Canada, and the US which incorporate our plato platform.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company has dosed seven patients with AVR-RD-01 across the investigator-sponsored Phase I clinical study and FAB-201 and the Phase II clinical trial in Fabry disease currently underway in Australia.

Additional preliminary clinical data from these trials is expected to be available this year.

The open-label, multinational FAB-201 study will evaluate the efficacy and safety of AVR-RD-01 in about eight to 12 treatment-naïve males, aged 16 years and older with Fabry disease.

During the second half of this year, the study will expand into the US and includes screening, baseline, pre-transplant, transplant, and post-transplant follow-up at 48 weeks.

After completion of the study, consenting subjects will continue periodic safety and efficacy assessments for about 14 years.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact